Galapagos NV Stock Euronext Bruxelles
Equities
GLPG
BE0003818359
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
27.26 EUR | 0.00% | 0.00% | 0.00% |
Sales 2024 * | 337M 359M | Sales 2025 * | 314M 335M | Capitalization | 1.8B 1.92B |
---|---|---|---|---|---|
Net income 2024 * | -44M -46.87M | Net income 2025 * | -65M -69.23M | EV / Sales 2024 * | -4.83 x |
Net cash position 2024 * | 3.43B 3.66B | Net cash position 2025 * | 3.13B 3.33B | EV / Sales 2025 * | -4.21 x |
P/E ratio 2024 * |
-28.6
x | P/E ratio 2025 * |
-21
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.64% |
Latest transcript on Galapagos NV
Managers | Title | Age | Since |
---|---|---|---|
Paulus Stoffels
CEO | Chief Executive Officer | 62 | 22-03-31 |
Thad Huston
DFI | Director of Finance/CFO | 54 | 23-05-31 |
Investor Relations Contact | - | 20-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Dickinson
BRD | Director/Board Member | 54 | Mar. 26 |
Jérôme Contamine
BRD | Director/Board Member | 66 | 22-04-25 |
Simon Sturge
BRD | Director/Board Member | 65 | 23-09-18 |
1st Jan change | Capi. | |
---|---|---|
-1.91% | 41.35B | |
+42.15% | 40.38B | |
+1.78% | 39.05B | |
-14.19% | 26.67B | |
+1.74% | 24.07B | |
-23.90% | 18.36B | |
-3.77% | 11.68B | |
+20.98% | 11.6B | |
+7.55% | 11.15B |
- Stock Market
- Equities
- GLPG Stock
- GLPG Stock